CARB-X funds Microbiotix to develop a novel oral antibiotic to treat multidrug resistant Gonorrhea

CARB-X is awarding Microbiotix, a US-based clinical-stage biopharmaceutical company in Worcester, MA, up to US$2.86 million in non-dilutive funding to develop a new oral antibiotic to treat multidrug-resistant gonorrhea, a sexually transmitted disease caused by bacteria that have developed resistance to all but one existing antibiotic.  If the project successfully achieves certain development milestones, Microbiotix will be eligible for an additional $16 million in funding from CARB-X.